X
<

Who's Watching Bioverativ Now?

PART:
1 2 3 4
Who's Watching Bioverativ Now? PART 1 OF 4

Behind Bioverativ’s Analyst Recommendations This September

Recent collaboration

In August 2017, Bioverativ (BIVV) and Invicro entered into a strategic collaboration in developing advanced imaging technologies for the diagnosis and treatment of joint diseases for individuals with hemophilia. The strategic collaboration primarily focuses on investigating the impact of Bioverativ’s Eloctate, Alprolix, and investigational BIVV001 on bleeding and long-term joint health.

In June 2017, Bioverativ acquired True North Therapeutics, a privately held biotechnology company. The acquisition of True North Therapeutics resulted in the addition of TNT009, an investigational monoclonal antibody for CAgD (cold agglutinin disease), to Bioverativ’s pipeline.

Behind Bioverativ&#8217;s Analyst Recommendations This September

Interested in ALXN? Don't miss the next report.

Receive e-mail alerts for new research on ALXN

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

Analyst recommendations

Of the 12 analysts tracking Bioverativ (BIVV) in September 2017, three have suggested a “strong buy” for the stock, while one has suggested a “buy.” Seven analysts have suggested a “hold,” and one analyst has suggested a “sell.”

Notably, ~33% analysts tracking Bioverativ in August 2017 suggested some form of a “buy” rating.

On September 4, 2017, Bioverativ had a mean 12-month target price of $64.44, which represents a ~15.2% return on investment. Notably, the First Trust NYSE Arca Biotechnology Index Fund (FBT) invests ~2.8% of its total portfolio in Bioverativ. FBT also invests ~3.2% in BioMarin Pharmaceuticals (BMRN), Bioverativ’s peer in the rare disease drug market.

Peer ratings

Of the 20 analysts tracking Alexion Pharmaceuticals (ALXN) in September 2017, ~80% recommended some form of “buy,” while four analysts suggested a “hold.” None recommended a “sell” or “strong sell” for Alexion. On September 4, 2017, Alexion had a mean 12-month target price of $158.95, which represents ~10.3% return over the next 12 months.

Of the 13 analysts tracking Neurocrine Biosciences (NBIX), all have recommended some form of “buy.” Five recommended a “strong buy,” while eight recommended a “buy.” On September 4, 2017, NBIX had a mean 12-month target price of $73.33, which represents 28.6% return over the next 12 months.

Of the 25 analysts tracking Vertex Pharmaceuticals (VRTX), ~80% have recommended some form of “buy.” Vertex has a 12-month mean target price of $178.09, which represents a 9.8% return over the next 12 months.

X

Please select a profession that best describes you: